Outcome according to response to prednisone measured in peripheral blood on day 8
| Variable . | Good response4-150 . | Poor response4-150 . | P (log rank)4-151 . | ||
|---|---|---|---|---|---|
| No. . | % EFS ± SE . | No. (%) . | % EFS ± SE . | ||
| Age, y | |||||
| <1 | 47 | 59 ± 7 | 11 (19) | 18 ± 12 | .003 |
| 1-9 | 1579 | 85 ± 1 | 123 (7.2) | 34 ± 4 | .0001 |
| ≥10 | 309 | 72 ± 3 | 68 (18.0) | 37 ± 6 | .0001 |
| WBC count (×109/L) | |||||
| <50 | 1591 | 85 ± 1 | 72 (4.3) | 45 ± 6 | .0001 |
| ≥50 | 344 | 71 ± 3 | 130 (27.4) | 28 ± 4 | .0001 |
| BFM-RF | |||||
| 1.2 to <1.7 | 511 | 79 ± 2 | 102 (16.6) | 30 ± 5 | .0001 |
| ≥1.7 | 98 | 66 ± 5 | 44 (31.0) | 25 ± 7 | .0001 |
| Immunophenotype | |||||
| Pro-B | 80 | 68 ± 6 | 19 (19.2) | 0‡ | .0001 |
| Common | 1274 | 84 ± 1 | 67 (5.0) | 46 ± 6 | .0001 |
| Pre-B | 338 | 79 ± 2 | 13 (3.7) | 31 ± 13 | .0001 |
| T cell | 180 | 78 ± 3 | 101 (35.9) | 32 ± 5 | .0001 |
| NCI risk group46 | |||||
| SR | 1324 | 87 ± 1 | 48 (3.5) | 45 ± 7 | .0001 |
| HR | 564 | 73 ± 2 | 143 (20.2) | 31 ± 4 | .0001 |
| Variable . | Good response4-150 . | Poor response4-150 . | P (log rank)4-151 . | ||
|---|---|---|---|---|---|
| No. . | % EFS ± SE . | No. (%) . | % EFS ± SE . | ||
| Age, y | |||||
| <1 | 47 | 59 ± 7 | 11 (19) | 18 ± 12 | .003 |
| 1-9 | 1579 | 85 ± 1 | 123 (7.2) | 34 ± 4 | .0001 |
| ≥10 | 309 | 72 ± 3 | 68 (18.0) | 37 ± 6 | .0001 |
| WBC count (×109/L) | |||||
| <50 | 1591 | 85 ± 1 | 72 (4.3) | 45 ± 6 | .0001 |
| ≥50 | 344 | 71 ± 3 | 130 (27.4) | 28 ± 4 | .0001 |
| BFM-RF | |||||
| 1.2 to <1.7 | 511 | 79 ± 2 | 102 (16.6) | 30 ± 5 | .0001 |
| ≥1.7 | 98 | 66 ± 5 | 44 (31.0) | 25 ± 7 | .0001 |
| Immunophenotype | |||||
| Pro-B | 80 | 68 ± 6 | 19 (19.2) | 0‡ | .0001 |
| Common | 1274 | 84 ± 1 | 67 (5.0) | 46 ± 6 | .0001 |
| Pre-B | 338 | 79 ± 2 | 13 (3.7) | 31 ± 13 | .0001 |
| T cell | 180 | 78 ± 3 | 101 (35.9) | 32 ± 5 | .0001 |
| NCI risk group46 | |||||
| SR | 1324 | 87 ± 1 | 48 (3.5) | 45 ± 7 | .0001 |
| HR | 564 | 73 ± 2 | 143 (20.2) | 31 ± 4 | .0001 |
EFS indicates event-free survival at 6 years; NCI, National Cancer Institute; SR, standard risk; and HR, high risk.
A good response to prednisone was defined as fewer than 1000/μL blasts in blood; a poor response was 1000/μL or more.
Based on a univariate comparison of EFS at 6 years between patients with a good response and those with a poor response in each patient subset.
There were 17 events in this subset.